Frederick J. Raal

36.3k total citations · 13 hit papers
341 papers, 14.4k citations indexed

About

Frederick J. Raal is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Frederick J. Raal has authored 341 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Surgery, 114 papers in Endocrinology, Diabetes and Metabolism and 70 papers in Economics and Econometrics. Recurrent topics in Frederick J. Raal's work include Lipoproteins and Cardiovascular Health (240 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (97 papers) and Health Systems, Economic Evaluations, Quality of Life (50 papers). Frederick J. Raal is often cited by papers focused on Lipoproteins and Cardiovascular Health (240 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (97 papers) and Health Systems, Economic Evaluations, Quality of Life (50 papers). Frederick J. Raal collaborates with scholars based in South Africa, United States and Netherlands. Frederick J. Raal's co-authors include Evan A. Stein, Scott M. Wasserman, Dirk Blom, Robert C. Scott, John J.P. Kastelein, Raúl D. Santos, Michael J. Koren, Jennifer G. Robinson, Kausik K. Ray and Gisle Langslet and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Frederick J. Raal

317 papers receiving 14.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015 1.7k citations Jennifer G. Robinson, Erik S.G. Stroes et al. profile →
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. profile →
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

2020 980 citations Kausik K. Ray, R. Scott Wright et al. profile →
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

2010 692 citations Frederick J. Raal, Raúl D. Santos et al. profile →
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

2014 562 citations Frederick J. Raal, Evan A. Stein et al. profile →
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

2020 562 citations Frederick J. Raal, David Kallend et al. profile →
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

2014 553 citations Frederick J. Raal, Dirk Blom et al. profile →
Evinacumab for Homozygous Familial Hypercholesterolemia

2020 470 citations Frederick J. Raal, Robert S. Rosenson et al. profile →
The Agenda for Familial Hypercholesterolemia

2015 450 citations Samuel S. Gidding, Mary Ann Champagne et al. Circulation profile →
Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

2012 403 citations Frederick J. Raal, Evan A. Stein et al. Circulation profile →
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. profile →
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

2021 159 citations R. Scott Wright, Kausik K. Ray et al. profile →
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

2022 131 citations Kausik K. Ray, Frederick J. Raal et al. European Heart Journal profile →

Peers

Countries citing papers authored by Frederick J. Raal

Since Specialization

Citations

This map shows the geographic impact of Frederick J. Raal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick J. Raal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick J. Raal more than expected).

Fields of papers citing papers by Frederick J. Raal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick J. Raal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick J. Raal. The network helps show where Frederick J. Raal may publish in the future.

Co-authorship network of co-authors of Frederick J. Raal

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick J. Raal. A scholar is included among the top collaborators of Frederick J. Raal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick J. Raal. Frederick J. Raal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lerodalcibep and adjudicated cardiovascular events in a pre-defined pooled analysis of three large long term Phase III studies 2025 ·Atherosclerosis ·David Kallend, Frederick J. Raal, (unknown), Eric Klug, Jeffrey Vest, Evan Stein	0
2	Predictive diagnostic models for newly diagnosed diabetes mellitus in moderate to severe COVID-19: the role of TyG Index, BMI, and inflammatory markers 2025 ·BMC Endocrine Disorders ·(unknown), (unknown), (unknown), Frederick J. Raal, Aletta M. E. Millen, Ismail Kalla	1
3	Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia 2025 ·Atherosclerosis ·(unknown), Eliot A. Brinton, (unknown), Frederick J. Raal, (unknown), (unknown), (unknown), Jean Bergeron, (unknown), (unknown), Shazia Ali, (unknown), Robert Pordy, Xue-Qiao Zhao, (unknown)	0
4	Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies 2024 ·Arteriosclerosis Thrombosis and Vascular Biology ·Frederick J. Raal, Robert A. Hegele, Andrea Ruzza, J. Antonio G. López, (unknown), (unknown), Huei Wang, Daniel Gaudet, Albert Wiegman, Jian Wang, Raúl D. Santos	9
5	SMASH: An initiative for equitable access to precision medicine for rare or severe lipid disorders 2024 ·(unknown), Marianne Abifadel, Alberico L. Catapano, Marina Cuchel, Raúl D. Santos, Frederick J. Raal, Daniel Gaudet	0
6	Evaluating the CURB-65 score for in-hospital mortality prediction in COVID-19 patients: insights into dysglycaemia 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Aletta M. E. Millen, Frederick J. Raal, Ismail Kalla	1
7	Inter-Individual Variability in LDL-C Reductions With Inclisiran—Pooled Data From ORION-10 and ORION-11 2023 ·Heart Lung and Circulation ·Peter J. Psaltis, Scott M. Wright, Frederick J. Raal, David Kallend, Robert M. Stoekenbroek, Wolfgang Köenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, P. Wijngaard, John J.P. Kastelein, Kausik K. Ray	1
8	Efficacy and Safety of Inclisiran According to Age: A Pooled Analysis of Phase III Studies (ORION 9, 10 and 11) 2023 ·Heart Lung and Circulation ·David Colquhoun, R. Scott Wright, Kausik K. Ray, Frederick J. Raal, David Kallend, Mark Jaros, Wolfgang Köenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, P. Wijngaard, John J.P. Kastelein	1
9	The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia 2023 ·JACC Advances ·Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp, John J.P. Kastelein, Paolo Rubba, P. Barton Duell, Masahiro Koseki, Erik S.G. Stroes, Shazia Ali, Poulabi Banerjee, Kuo‐Chen Chan, Nagwa Khilla, Jennifer McGinniss, Robert Pordy, Yi Zhang, Daniel Gaudet	15
10	Inclisiran and cardiovascular events: a patient-level analysis of phase III trials breakdown → 2022 ·European Heart Journal ·Kausik K. Ray, Frederick J. Raal, David Kallend, Mark Jaros, Wolfgang Köenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, David Lawrence, Andrew Friedman, Lorena Garcia Conde, R. Scott Wright, (unknown)	131
11	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials 2022 ·Journal of clinical lipidology ·(unknown), Robert P. Giugliano, Marc S. Sabatine, Frederick J. Raal, Tamio Teramoto, Michael J. Koren, Evan A. Stein, Huei Wang, Maria Laura Monsalvo	6
12	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia 2021 ·Atherosclerosis ·Julia Brandts, Kanika Dharmayat, Antonio J. Vallejo‐Vaz, Mansour T. A. Sharabiani, Rebecca Jones, John J.P. Kastelein, Frederick J. Raal, Kausik K. Ray	20
13	Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment 2021 ·Atherosclerosis ·Alpo Vuorio, Frederick J. Raal, Markku Kaste, Petri T. Kovanen	20
14	Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature 2020 ·SHILAP Revista de lepidopterología ·(unknown), Neil Butkow, Frederick J. Raal, Tobias Chirwa, Alan Rothberg	2
15	Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council 2015 ·Arteriosclerosis Thrombosis and Vascular Biology ·Robert A. Hegele, Samuel S. Gidding, Henry N. Ginsberg, Ruth McPherson, Frederick J. Raal, Daniel J. Rader, Jennifer G. Robinson, Francine K. Welty	52
16	South African Dyslipidaemia Guideline Consensus Statement 2015 ·SHILAP Revista de lepidopterología ·(unknown), Frederick J. Raal, (unknown), Marja‐Riitta Taskinen, (unknown), Colin Schamroth, (unknown), David Jankelow, Dirk Blom, (unknown), David Webb	2
17	The Agenda for Familial Hypercholesterolemia breakdown → 2015 ·Circulation ·Samuel S. Gidding, Mary Ann Champagne, Sarah D. de Ferranti, Joep C. Defesche, Matthew K. Ito, Joshua W. Knowles, Brian W. McCrindle, Frederick J. Raal, Daniel J. Rader, Raúl D. Santos, Maria F. Lopes‐Virella, Gerald F. Watts, Anthony S. Wierzbicki	450
18	The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). 2008 ·PubMed ·(unknown), Neil Butkow, Frederick J. Raal, (unknown)	3
19	Performance of the CardioChekTM PA and Cholestech LDX(R) point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids : cardiovascular topic 2005 ·Vanessa R. Panz, Frederick J. Raal, Janice Paiker, (unknown), (unknown)	11
20	Functional foods with added plant sterols for treatment of hypercholesterolaemia and prevention of ischaemic heart disease 2003 ·South African Journal of Clinical Nutrition ·H H Vorster, Frederick J. Raal, (unknown), A. David Marais, (unknown), Fady Ntanios	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact